![](https://library.celltelligence.com/wp-content/uploads/2021/01/EMA_Announcement.png)
$0
CHMP Adopts Positive Opinion for Yescarta; Breyanzi Absent from September’s CHMP Highlights
On Friday, September 16, the CHMP meeting highlights were released following Monday’s CHMP agenda. Of note, the CHMP adopted a positive opinion for Yescarta (Gilead / Kite’s CD19 CAR-T) in 2L LBCL. Additionally, Breyanzi (BMS’s CD19 CAR-T) was absent from the CHMP highlights. Below, Celltelligence provides insights on Yescarta’s positive opinion, while discussing updated EU timelines for Breyanzi.